公开(公告)号：US20180303817A1

公开(公告)日：2018-10-25

申请号：US15771193

申请日：2016-12-15

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Saori Miyano ,  Yuji Yamamoto ,  Takayuki Nakagawa

IPC: A61K31/4545 ,  A61P35/04

CPC classification number: A61K31/4545 ,  A61P35/04

Abstract: The present application discloses a therapeutic agent for breast cancer, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

公开(公告)号：US20230172924A1

公开(公告)日：2023-06-08

申请号：US18008304

申请日：2021-07-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Satoshi KAWANO ,  Saori Miyano ,  Kyoko NISHIBATA ,  Sayo FUKUSHIMA

IPC: A61K31/4545 ,  A61K31/565 ,  A61K31/4196 ,  A61K31/566 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61K31/565 ,  A61K31/4196 ,  A61K31/566 ,  A61P35/00

Abstract: Disclosed is a therapeutic agent for breast cancer, said therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof that is to be administered in combination with an estrogen receptor antagonist or an aromatase inhibitor.

公开(公告)号：US20210333281A1

公开(公告)日：2021-10-28

申请号：US17282218

申请日：2019-10-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Yukinori Minoshima ,  Michio Kanekiyo ,  Saori Miyano ,  Taisuke Hoshi

IPC: G01N33/574 ,  A61K31/47 ,  A61P35/00 ,  C12Q1/6886

Abstract: Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising soratenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

公开(公告)号：US11219619B2

公开(公告)日：2022-01-11

申请号：US16970683

申请日：2019-03-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Atsumi Yamaguchi ,  Hajime Shimizu ,  Satoshi Goda ,  Saori Miyano

IPC: A61K31/4545 ,  A61K45/06

Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

公开(公告)号：US20200375970A1

公开(公告)日：2020-12-03

申请号：US16970683

申请日：2019-03-26

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Atsumi Yamaguchi ,  Hajime Shimizu ,  Satoshi Goda ,  Saori Miyano

IPC: A61K31/4545 ,  A61K45/06

Abstract: Disclosed is a therapeutic agent for hepatocellular carcinoma, comprising 5-((2-(4-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.